DE69321962T2 - Von tat abgeleitete transportpolypeptide - Google Patents

Von tat abgeleitete transportpolypeptide

Info

Publication number
DE69321962T2
DE69321962T2 DE69321962T DE69321962T DE69321962T2 DE 69321962 T2 DE69321962 T2 DE 69321962T2 DE 69321962 T DE69321962 T DE 69321962T DE 69321962 T DE69321962 T DE 69321962T DE 69321962 T2 DE69321962 T2 DE 69321962T2
Authority
DE
Germany
Prior art keywords
tat
absence
polypeptides
amino acids
transport polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69321962T
Other languages
English (en)
Other versions
DE69321962D1 (de
Inventor
James Barsoum
Stephen Fawell
R Pepinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DE69321962D1 publication Critical patent/DE69321962D1/de
Publication of DE69321962T2 publication Critical patent/DE69321962T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69321962T 1992-08-21 1993-08-19 Von tat abgeleitete transportpolypeptide Expired - Lifetime DE69321962T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93437592A 1992-08-21 1992-08-21
PCT/US1993/007833 WO1994004686A1 (en) 1992-08-21 1993-08-19 Tat-derived transport polypeptides

Publications (2)

Publication Number Publication Date
DE69321962D1 DE69321962D1 (de) 1998-12-10
DE69321962T2 true DE69321962T2 (de) 1999-07-01

Family

ID=25465458

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69321962T Expired - Lifetime DE69321962T2 (de) 1992-08-21 1993-08-19 Von tat abgeleitete transportpolypeptide
DE0656950T Pending DE656950T1 (de) 1992-08-21 1993-08-19 Tat-derivate transport polypeptide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0656950T Pending DE656950T1 (de) 1992-08-21 1993-08-19 Tat-derivate transport polypeptide.

Country Status (14)

Country Link
EP (3) EP0903408A3 (de)
JP (2) JP2702285B2 (de)
KR (1) KR0153027B1 (de)
AT (1) ATE173016T1 (de)
AU (1) AU667244B2 (de)
CA (1) CA2135642C (de)
DE (2) DE69321962T2 (de)
DK (1) DK0656950T3 (de)
ES (1) ES2123062T3 (de)
FI (1) FI120495B (de)
HK (1) HK1012678A1 (de)
NO (1) NO316761B1 (de)
NZ (1) NZ255831A (de)
WO (1) WO1994004686A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US6623938B2 (en) 1997-01-21 2003-09-23 Human Genome Sciences, Inc. I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
US6306993B1 (en) 1997-05-21 2001-10-23 The Board Of Trustees Of The Leland Stanford, Jr. University Method and composition for enhancing transport across biological membranes
EP2085090A3 (de) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitoren von immunstimulatorischen DNA Sequenz Aktivität
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU755564B2 (en) * 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
WO2000038733A1 (en) * 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU7473500A (en) * 1999-09-01 2001-03-26 University Of Pittsburgh Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU3368301A (en) * 2000-01-07 2001-07-16 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
KR100379578B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
EP2149604A1 (de) 2000-09-08 2010-02-03 Universität Zürich Entnahme von Repeat-Proteinen mit Repeat-Modulen
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
DE60233137D1 (de) 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
WO2002099104A1 (fr) * 2001-06-05 2002-12-12 Pola Chemical Industries Inc. Polypeptide destabilisant une proteine dans des cellules dans des conditions aerobies et adn codant pour ce polypeptide
KR100495138B1 (ko) * 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
US20070136825A1 (en) 2001-09-18 2007-06-14 Wolf-Bernd Frommer Fusion proteins useful for detecting analytes
WO2003035892A2 (en) * 2001-10-19 2003-05-01 The Scripps Research Institute Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
AU2003201733B2 (en) 2002-01-09 2008-11-06 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7026166B2 (en) 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
EP1495124A2 (de) * 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptide zur verwendung als therapeutische mittel gegen krebs und autoimmunerkrankungen
EP1354953A1 (de) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-Peptide zur Verwendung als therapeutische Mittel gegen Krebs und Autoimmunerkrankungen
WO2003089457A2 (en) 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c ϝ for pain management
KR100472939B1 (ko) * 2002-05-24 2005-03-18 학교법인 한림대학교 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도
US7862807B2 (en) 2002-07-19 2011-01-04 University Of California, San Diego Dendrimers as molecular translocators
KR100472938B1 (ko) * 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
EP1629105B1 (de) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen
WO2005035562A1 (ja) * 2003-10-07 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 新規な細胞増殖促進剤
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
CN101083907B (zh) 2004-03-03 2012-10-10 雷文斯治疗公司 用于局部诊断剂和治疗剂运输的组合物和方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
JP4474264B2 (ja) * 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
EP1988167B1 (de) * 2005-02-17 2020-04-01 Sorbonne Universite Intrazellular hemmende Peptide
EP1861112A4 (de) 2005-03-03 2009-07-22 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinumtoxinen
RU2007136617A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрезкожного введения олигопептида
WO2006094813A2 (en) 2005-03-10 2006-09-14 Nascacell Technologies Ag. Dimeric or multimeric microproteins
US7973084B2 (en) 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
KR100699279B1 (ko) 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
IL296832A (en) 2005-10-18 2022-11-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
US7517959B2 (en) 2005-11-11 2009-04-14 Walter And Eliza Hall Institute Of Medical Research SOCS3 proteins
PL2436696T3 (pl) 2007-01-05 2017-10-31 Univ Zuerich Sposób wytwarzania specyficznych dla choroby cząsteczek wiążących i struktur docelowych
EP2134852A4 (de) 2007-03-13 2010-04-28 Nat Jewish Health Verfahren zur erzeugung von antikörpern
CN101652388B (zh) 2007-03-13 2013-12-25 苏黎世大学 单克隆人肿瘤特异性抗体
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
PT3120862T (pt) 2007-07-26 2020-06-25 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
EP2527369A3 (de) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoklonaler amyloid-beta (abeta)-spezifischer Antikörper und seine Verwendung
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
ES2671024T3 (es) 2008-02-28 2018-06-04 Toray Industries, Inc. Composición farmacéutica para administración transnasal
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP5762286B2 (ja) 2008-07-21 2015-08-12 タイガ バイオテクノロジーズ，インク． 分化無核細胞、及び該無核細胞の作成方法
AU2009279682B2 (en) 2008-08-04 2015-01-22 University Of Miami STING (stimulator of interferon genes), a regulator of innate immune responses
WO2010025421A2 (en) 2008-08-28 2010-03-04 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2433953B1 (de) 2009-05-20 2015-07-08 Toray Industries, Inc. Zellmembranpermeable peptide
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9084746B2 (en) * 2010-09-22 2015-07-21 The Regents Of The University Of Colorado, A Body Corporate Therapeutic applications of SMAD7
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CN103347898B (zh) 2011-01-10 2017-12-05 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
EP2714743A1 (de) 2011-06-03 2014-04-09 CT Atlantic Ltd. Magea3-bindende antikörper
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
EP2797951B1 (de) 2011-12-28 2018-01-31 ImmunoQure AG Verfahren zur isolierung von menschlichen antikörpern
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
CN105358704B (zh) 2013-03-08 2020-01-03 科罗拉多大学董事会 Ptd-smad7治疗剂
CA2940513C (en) * 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2903275A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3016978B1 (de) 2013-07-03 2022-01-26 ImmunoQure AG Menschliche anti-ifn-alpha antikörper
ES2911714T3 (es) 2014-03-11 2022-05-20 Univ Florida Proteína M013 expresada por AAV como un terapéutico antiinflamatorio para su uso en un método de tratamiento de enfermedad ocular inflamatoria
JP6468722B2 (ja) * 2014-04-30 2019-02-13 日本信号株式会社 物体検出装置
JP2018517712A (ja) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
JP2018517711A (ja) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー 細胞表面タンパク質に対する抗体を作製する方法
CN107922950B (zh) 2015-06-01 2021-12-31 基因医疗免疫疗法有限责任公司 T细胞受体文库
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
US11535654B2 (en) 2015-06-11 2022-12-27 Keio University Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, DNA, and vector
CA3009564C (en) 2015-12-23 2023-08-29 Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Dendritic cell composition
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
SG10202012839TA (en) 2016-12-19 2021-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US20220048953A1 (en) 2018-09-26 2022-02-17 Kaneka Corporation Cell-penetrating peptide
JPWO2022154079A1 (de) * 2021-01-18 2022-07-21

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0506884T3 (da) * 1989-12-21 1996-11-04 Whitehead Biomedical Inst Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors

Also Published As

Publication number Publication date
JPH07503617A (ja) 1995-04-20
NO944273L (no) 1995-02-17
FI945248A (fi) 1995-01-05
AU5083293A (en) 1994-03-15
NO316761B1 (no) 2004-05-03
FI120495B (fi) 2009-11-13
EP0656950B1 (de) 1998-11-04
JP2702285B2 (ja) 1998-01-21
EP0903408A2 (de) 1999-03-24
WO1994004686A1 (en) 1994-03-03
EP0903408A3 (de) 2005-11-02
JP2869396B2 (ja) 1999-03-10
AU667244B2 (en) 1996-03-14
NZ255831A (en) 1997-04-24
ATE173016T1 (de) 1998-11-15
FI945248A0 (fi) 1994-11-08
KR0153027B1 (en) 1998-10-15
NO944273D0 (no) 1994-11-09
HK1012678A1 (en) 1999-08-06
EP2000536A3 (de) 2010-06-30
DE69321962D1 (de) 1998-12-10
CA2135642A1 (en) 1994-03-03
EP2000536A2 (de) 2008-12-10
DK0656950T3 (da) 1999-07-19
DE656950T1 (de) 1996-03-14
EP0656950A1 (de) 1995-06-14
CA2135642C (en) 1999-12-14
ES2123062T3 (es) 1999-01-01
JPH1033186A (ja) 1998-02-10

Similar Documents

Publication Publication Date Title
DE69321962D1 (de) Von tat abgeleitete transportpolypeptide
Habeeb Chemical evaluation of conformational differences in native and chemically modified proteins
GB9720054D0 (en) Biological products
FI913637A0 (fi) Foer epitelceller specifik dna kodande vaextfaktor.
ATE256186T1 (de) Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
ES2103266T3 (es) Procedimiento de dna recombinante y celulas huesped.
NO20012017L (no) Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose
Staros et al. Cross-linking and chymotryptic digestion of the extractoplasmic domain of the anion exchange channel in intact human erythrocytes
DE69132545D1 (de) Protein mit Cytokinaktivität, Rekombinant-DNS, Expressionsvektor und Wirtszellen zu seiner Herstellung
DE69231567D1 (de) Screeningverfahren von morphogenischen Proteinen
ES2240971T3 (es) Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.
Carsten Tropomyosin from smooth muscle of the uterus
DE3273606D1 (en) Process for the purification or concentration of biologically active proteins, and appropriate means therefor
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
BR9303903A (pt) Fator-4 de plaqueta modificado ou clivado e processo para sua preparaçao, formulaçao farmacêutica, composto e vetor de dna recombinante e célula hospedeira
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
ATE205538T1 (de) Genregulatorische sequenzen von cd4, welche spezifisch in reifen t-zellen exprimiert werden
ATE277176T1 (de) Faltende proteine
許奎晶 Small GTP-binding Proteins
Perraudin et al. Disulfide content of reduced hen egg white and human milk lysozymes during the folding process
PT97820A (pt) Processo de obtencao de proteina map2-quinases, de microorganismos e linhas de celulas compreendendo moleculas recombinantes de map2-quinase e de detencao da presenca de actividade de factores celulares
KR950023648A (ko) 생물학적 활성을 나타내는 폴리펩티드
TH23717A (th) ธรอมโบพอยเอติน
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US